Literature DB >> 28538441

Hyperlactatemia, Lactate Kinetics and Prediction of Citrate Accumulation in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy With Regional Citrate Anticoagulation.

Dmytro Khadzhynov1, Annette Dahlinger, Christin Schelter, Harm Peters, Detlef Kindgen-Milles, Klemens Budde, Lukas Johannes Lehner, Fabian Halleck, Oliver Staeck, Torsten Slowinski.   

Abstract

OBJECTIVES: Citrate accumulation is a major complication of regional citrate anticoagulation during continuous renal replacement therapy. We studied the prediction of citrate accumulation during continuous veno-venous hemodialysis with regional citrate anticoagulation by initial lactate concentrations and lactate kinetics.
DESIGN: A retrospective follow-up analysis from a cohort of critically ill patients.
SETTING: Mixed medical-surgical ICUs at a university hospital. PATIENTS: All adult patients with acute kidney injury and treated with regional citrate anticoagulation-continuous veno-venous hemodialysis during a 3-year period (n = 1,070) were included in this retrospective study and screened for metabolic signs of citrate accumulation.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The frequency of citrate accumulation during the first 48 hours of therapy was 2.26%. In patients with initial normal lactate (< 2.2 mmol/L), elevated lactate (≥ 2.2 to < 4 mmol/L), or severe hyperlactatemia (≥ 4 mmol/L), the frequency of citrate accumulation was 0.77%, 2.70%, and 6.33%, respectively. Receiver operating characteristics-area under the curve of initial lactate concentration was 0.789 for the prediction of citrate accumulation. Optimal cutoff from receiver operating characteristics (2.39 mmol/L) showed strong negative prediction (99.28%), but weak positive prediction (5.21%). The slope intercept of lactate kinetics over 48 hours was positive and significantly higher in patients with citrate accumulation compared to those without (+0.2 vs -0.006 mmol/L/hr; p < 0.001). In patients with initial severe hyperlactatemia (≥ 4 mmol/L), the median calculated lactate clearance at 6, 12, and 18 hours was 24.0%, 48.1%, and 59.4% in the nonaccumulation group. These clearance rates were significantly higher at each time-point compared to patients with citrate accumulation (-9.8%, -20.5%, and 2.3%, respectively; p < 0.001 for each time-point). The highest receiver operating characteristics-area under the curve for citrate accumulation was observed for 12-hour values of lactate clearance (area under the curve = 0.839; 95% CI, 0.751-0.927) with an optimal cut-off value of 24.3%.
CONCLUSIONS: Risk of citrate accumulation during regional citrate anticoagulation in a well-selected cohort of patients is low even in case of initial severe hyperlactatemia. Lactate kinetics rather than initially elevated lactate concentration should be considered in assessing the risk of citrate accumulation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28538441     DOI: 10.1097/CCM.0000000000002501

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

Review 1.  [Regional citrate anticoagulation in renal replacement therapy in the intensive care station : Recommendations from the renal section of the DGIIN, ÖGIAIN and DIVI].

Authors:  M Schmitz; M Joannidis; D Czock; S John; A Jörres; S J Klein; M Oppert; V Schwenger; J Kielstein; A Zarbock; D Kindgen-Milles; C Willam
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-05-08       Impact factor: 0.840

Review 2.  Renal replacement therapy: a practical update.

Authors:  George Alvarez; Carla Chrusch; Terry Hulme; Juan G Posadas-Calleja
Journal:  Can J Anaesth       Date:  2019-02-06       Impact factor: 5.063

3.  Long-term continuous renal replacement therapy and anticoagulation with citrate in critically ill patients with severe liver dysfunction.

Authors:  Matthias Klingele; Theresa Stadler; Danilo Fliser; Timo Speer; Heinrich V Groesdonk; Alexander Raddatz
Journal:  Crit Care       Date:  2017-11-29       Impact factor: 9.097

4.  A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding.

Authors:  Jianping Gao; Feng Wang; Yonggang Wang; Dan Jin; Liping Tang; Konghan Pan
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

5.  Inducible metabolic pathway for citrate metabolism in case of major liver dysfunction: fact or fiction?

Authors:  Patrick M Honore; David De Bels; Sebastien Redant; Rachid Attou; Luc Kugener; Willem Boer
Journal:  Crit Care       Date:  2019-05-14       Impact factor: 9.097

6.  Lymphoma total lesion glycolysis leads to hyperlactatemia and reduction of brain glucose utilization.

Authors:  Hyun Kyung Yi; Jang Yoo; Seok Jin Kim; Joon Young Choi; Kyung-Han Lee
Journal:  Sci Rep       Date:  2022-07-25       Impact factor: 4.996

7.  Development and External Validation of a Model for Predicting Sufficient Filter Lifespan in Anticoagulation-Free Continuous Renal Replacement Therapy Patients.

Authors:  Wei Zhang; Ming Bai; Ling Zhang; Yan Yu; Yangping Li; Lijuan Zhao; Yuan Yue; Yajuan Li; Min Zhang; Ping Fu; Shiren Sun; Xiangmei Chen
Journal:  Blood Purif       Date:  2021-10-21       Impact factor: 3.348

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.